<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Catalyst Calendar - Imugene (IMU.AX) Stock Analysis</title>
    <link rel="stylesheet" href="css/style.css">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.0.0-beta3/css/all.min.css">
    <meta name="robots" content="noindex, nofollow">
</head>
<body>
    <div class="sidebar">
        <div class="sidebar-title">
            Imugene Analysis
        </div>
        <ul class="sidebar-nav">
            <li><a href="index.html"><i class="fas fa-home"></i> Overview</a></li>
            <li><a href="financial_analysis.html"><i class="fas fa-chart-line"></i> Financial Analysis</a></li>
            <li><a href="clinical_trials.html"><i class="fas fa-flask"></i> Clinical Trials</a></li>
            <li><a href="technical_analysis.html"><i class="fas fa-chart-bar"></i> Technical Analysis</a></li>
            <li><a href="short_selling_analysis.html"><i class="fas fa-arrow-down"></i> Short Selling</a></li>
            <li><a href="market_position.html"><i class="fas fa-building"></i> Competitor Analysis</a></li>
            <li><a href="investment_recommendations.html"><i class="fas fa-lightbulb"></i> Investment Thesis</a></li>
            <li><a href="options_trading.html"><i class="fas fa-exchange-alt"></i> Options Trading</a></li>
            <li><a href="csl_case_study.html"><i class="fas fa-microscope"></i> CSL Case Study</a></li>
            <li><a href="catalyst_calendar.html" class="active"><i class="fas fa-calendar-alt"></i> Catalyst Calendar</a></li>
        </ul>
    </div>

    <div class="main-content">
        <div class="page-header">
            <h1 class="page-title">Catalyst Calendar - Imugene (IMU.AX)</h1>
            <div class="header-actions">
                <button class="btn"><i class="fas fa-share-alt"></i> Share</button>
                <button class="btn"><i class="fas fa-file-export"></i> Export</button>
                <button class="btn btn-primary"><i class="fas fa-calendar-week"></i> This week</button>
            </div>
        </div>

        <section class="section">
            <h2 class="section-title">Upcoming Catalysts Timeline</h2>
            <div class="card">
                <h3 class="card-title">Imugene's Clinical and Corporate Catalysts</h3>
                <p>The chart below shows Imugene's clinical trial timeline with key milestones and data readout points that could serve as significant share price catalysts.</p>
                <img src="img/clinical_trial_gantt_chart.png" alt="Clinical Trial Timeline">
                
                <h4 class="card-subtitle">Key Dates and Milestones</h4>
                <p>This calendar highlights the most significant upcoming events that could impact Imugene's share price and business prospects.</p>
            </div>
        </section>

        <section class="section">
            <h2 class="section-title">Q2 2025 (April-June)</h2>
            <div class="card">
                <h3 class="card-title">Near-Term Catalysts</h3>
                
                <table>
                    <thead>
                        <tr>
                            <th>Date</th>
                            <th>Event</th>
                            <th>Program</th>
                            <th>Potential Impact</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>April 15, 2025</td>
                            <td>Quarterly Cash Flow Report</td>
                            <td>Corporate</td>
                            <td>Medium - Will update cash runway projections</td>
                        </tr>
                        <tr>
                            <td>May 8-12, 2025</td>
                            <td>ASCO Abstract Release</td>
                            <td>Azer-cel (DLBCL)</td>
                            <td>High - First look at Phase 1b expansion cohort data</td>
                        </tr>
                        <tr>
                            <td>June 2-6, 2025</td>
                            <td>ASCO Annual Meeting Presentation</td>
                            <td>Azer-cel (DLBCL)</td>
                            <td>Very High - Detailed Phase 1b data presentation</td>
                        </tr>
                        <tr>
                            <td>June 20, 2025</td>
                            <td>FDA Meeting</td>
                            <td>Azer-cel (DLBCL)</td>
                            <td>High - End of Phase 1 meeting to discuss Phase 2 design</td>
                        </tr>
                    </tbody>
                </table>
                
                <h4 class="card-subtitle">Q2 2025 Outlook</h4>
                <p>The second quarter of 2025 represents a critical period for Imugene, with the ASCO presentation of Azer-cel data being potentially the most significant catalyst of the year. Strong data could drive substantial share price appreciation and potentially attract partnership interest.</p>
            </div>
        </section>

        <section class="section">
            <h2 class="section-title">Q3 2025 (July-September)</h2>
            <div class="card">
                <h3 class="card-title">Mid-Term Catalysts</h3>
                
                <table>
                    <thead>
                        <tr>
                            <th>Date</th>
                            <th>Event</th>
                            <th>Program</th>
                            <th>Potential Impact</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>July 15, 2025</td>
                            <td>Quarterly Cash Flow Report</td>
                            <td>Corporate</td>
                            <td>High - Critical cash position update as runway shortens</td>
                        </tr>
                        <tr>
                            <td>August 2025</td>
                            <td>Cash Runway End</td>
                            <td>Corporate</td>
                            <td>Very High - Financing likely required</td>
                        </tr>
                        <tr>
                            <td>August 25, 2025</td>
                            <td>Annual Results Announcement</td>
                            <td>Corporate</td>
                            <td>Medium - Financial results and outlook</td>
                        </tr>
                        <tr>
                            <td>September 15, 2025</td>
                            <td>Preliminary Data Release</td>
                            <td>CF33/VAXINIA (Bile Tract)</td>
                            <td>High - First efficacy signals from Phase 1 trial</td>
                        </tr>
                    </tbody>
                </table>
                
                <h4 class="card-subtitle">Q3 2025 Outlook</h4>
                <p>The third quarter presents significant challenges and opportunities. The approaching cash runway end will likely necessitate a capital raise, which could pressure the share price. However, positive preliminary data from the CF33/VAXINIA bile tract program could provide offsetting positive momentum.</p>
            </div>
        </section>

        <section class="section">
            <h2 class="section-title">Q4 2025 (October-December)</h2>
            <div class="card">
                <h3 class="card-title">Late 2025 Catalysts</h3>
                
                <table>
                    <thead>
                        <tr>
                            <th>Date</th>
                            <th>Event</th>
                            <th>Program</th>
                            <th>Potential Impact</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>October 15, 2025</td>
                            <td>Quarterly Cash Flow Report</td>
                            <td>Corporate</td>
                            <td>Medium - First report after expected financing</td>
                        </tr>
                        <tr>
                            <td>November 5-9, 2025</td>
                            <td>SITC Annual Meeting</td>
                            <td>PD1-Vaxx (NSCLC)</td>
                            <td>Medium - Phase 1b data update</td>
                        </tr>
                        <tr>
                            <td>November 20, 2025</td>
                            <td>Annual General Meeting</td>
                            <td>Corporate</td>
                            <td>Medium - Strategic updates and outlook</td>
                        </tr>
                        <tr>
                            <td>December 7-10, 2025</td>
                            <td>ASH Annual Meeting</td>
                            <td>Azer-cel (DLBCL)</td>
                            <td>High - Updated Phase 1b data with longer follow-up</td>
                        </tr>
                    </tbody>
                </table>
                
                <h4 class="card-subtitle">Q4 2025 Outlook</h4>
                <p>The fourth quarter features important scientific conferences where Imugene will present updated clinical data. The ASH meeting in December will be particularly important for the Azer-cel program, potentially providing longer-term follow-up data on durability of responses.</p>
            </div>
        </section>

        <section class="section">
            <h2 class="section-title">2026 Outlook</h2>
            <div class="card">
                <h3 class="card-title">Long-Term Catalysts</h3>
                
                <table>
                    <thead>
                        <tr>
                            <th>Timeframe</th>
                            <th>Event</th>
                            <th>Program</th>
                            <th>Potential Impact</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>Q1 2026</td>
                            <td>Phase 2 Initiation</td>
                            <td>Azer-cel (DLBCL)</td>
                            <td>High - Pivotal trial commencement</td>
                        </tr>
                        <tr>
                            <td>Q1 2026</td>
                            <td>Phase 1 Data Release</td>
                            <td>CF33/VAXINIA (Solid Tumors)</td>
                            <td>High - Complete Phase 1 results</td>
                        </tr>
                        <tr>
                            <td>Q2 2026</td>
                            <td>Phase 1 Data Release</td>
                            <td>CF33/VAXINIA (Bile Tract)</td>
                            <td>High - Complete Phase 1 results</td>
                        </tr>
                        <tr>
                            <td>H2 2026</td>
                            <td>Potential Partnership Announcement</td>
                            <td>Corporate/Multiple Programs</td>
                            <td>Very High - Validation and non-dilutive funding</td>
                        </tr>
                    </tbody>
                </table>
                
                <h4 class="card-subtitle">2026 Strategic Outlook</h4>
                <p>2026 represents a potential inflection point for Imugene as multiple programs will have generated meaningful clinical data. The company will likely pursue strategic partnerships to advance later-stage development without bearing the full financial burden. Successful execution could position Imugene for significant value creation.</p>
            </div>
        </section>

        <section class="section">
            <h2 class="section-title">Catalyst Risk Assessment</h2>
            <div class="card">
                <h3 class="card-title">Risk Factors for Key Catalysts</h3>
                
                <h4 class="card-subtitle">Clinical Data Risks</h4>
                <ul>
                    <li><strong>Patient Recruitment Delays:</strong> Could push back expected data readout timelines</li>
                    <li><strong>Data Quality Issues:</strong> Small sample sizes may limit statistical significance</li>
                    <li><strong>Competitive Developments:</strong> Advances by competitors could diminish impact of Imugene's results</li>
                </ul>
                
                <h4 class="card-subtitle">Corporate Event Risks</h4>
                <ul>
                    <li><strong>Financing Terms:</strong> Dilutive capital raises could pressure share price</li>
                    <li><strong>Management Changes:</strong> Potential departures of key executives could create uncertainty</li>
                    <li><strong>Partnership Negotiations:</strong> Delays or unfavorable terms could disappoint market expectations</li>
                </ul>
                
                <h4 class="card-subtitle">Regulatory Risks</h4>
                <ul>
                    <li><strong>FDA Feedback:</strong> Requests for additional data could delay development timelines</li>
                    <li><strong>Clinical Hold Potential:</strong> Safety concerns could temporarily pause clinical trials</li>
                    <li><strong>Changing Regulatory Standards:</strong> Evolving requirements for approval in oncology</li>
                </ul>
            </div>
        </section>

        <section class="section">
            <h2 class="section-title">Investment Strategy Around Catalysts</h2>
            <div class="card">
                <h3 class="card-title">Positioning for Key Events</h3>
                
                <h4 class="card-subtitle">Pre-Catalyst Strategies</h4>
                <ul>
                    <li><strong>Position Sizing:</strong> Consider increasing position size 2-4 weeks before major data readouts</li>
                    <li><strong>Risk Management:</strong> Set clear stop-loss levels to protect against negative outcomes</li>
                    <li><strong>Options Strategies:</strong> Consider using options to gain leveraged exposure with defined risk</li>
                </ul>
                
                <h4 class="card-subtitle">Post-Catalyst Strategies</h4>
                <ul>
                    <li><strong>Positive Outcome:</strong> Consider taking partial profits while maintaining core position</li>
                    <li><strong>Negative Outcome:</strong> Assess severity and long-term implications before making decisions</li>
                    <li><strong>Mixed/Ambiguous Outcome:</strong> Wait for analyst interpretations and management commentary</li>
                </ul>
                
                <p>The most significant near-term catalyst is the ASCO presentation in June 2025, which warrants particular attention from investors. Strong data could drive substantial share price appreciation, while disappointing results could lead to significant downside.</p>
            </div>
        </section>

        <footer>
            <p>Imugene (IMU.AX) Investment Analysis - April 2025</p>
            <p><a href="https://github.com/Hodge2Franklin/Imugene" target="_blank">View on GitHub</a></p>
        </footer>
    </div>
</body>
</html>
